Trial · NCT03036098
Results by group70
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 70
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary Study | Treatment 1 | 19.06 | 95% Confidence Interval 13.47 to 22.60 | Months | |
| Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary Study | Treatment 2 | 13.21 | 95% Confidence Interval 11.63 to 15.24 | Months | |
| Overall Survival (OS) in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Randomized Participants by Immunohistochemistry (IHC) for Primary Study | Treatment 1 | 16.30 | 95% Confidence Interval 11.53 to 21.82 | Months | |
| Overall Survival (OS) in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Randomized Participants by Immunohistochemistry (IHC) for Primary Study | Treatment 2 | 14.36 | 95% Confidence Interval 10.48 to 17.64 | Months | |
| Overall Survival (OS) in All Randomized Participants for Primary Study | Treatment 1 | 18.76 | 95% Confidence Interval 15.05 to 21.82 | Months | |
| Overall Survival (OS) in All Randomized Participants for Primary Study | Treatment 2 | 14.32 | 95% Confidence Interval 12.22 to 15.87 | Months | |
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Cisplatin-ineligible Randomized Participants for Primary Study | Treatment 1 | 5.29 | 95% Confidence Interval 3.78 to 5.95 | Months | |
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Cisplatin-ineligible Randomized Participants for Primary Study | Treatment 2 | 5.88 | 95% Confidence Interval 5.62 to 7.59 | Months | |
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Participants for Primary Study | Treatment 1 | 5.39 | 95% Confidence Interval 3.75 to 7.39 | Months | |
Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Participants for Primary Study | Treatment 2 | 5.78 | 95% Confidence Interval 4.80 to 6.93 | Months | |
| Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in All Randomized Participants for Primary Study | Treatment 1 | 5.03 | 95% Confidence Interval 3.94 to 5.98 | Months | |
| Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in All Randomized Participants for Primary Study | Treatment 2 | 6.01 | 95% Confidence Interval 5.78 to 7.52 | Months | |
Change From Baseline in the European Organization for Research and Treatment of Care Quality-of-Life Questionnaire (EORTC QLQ-C30) Global Health Status Score in All Randomized Participants for Primary Study | Treatment 1 | Global Health Status - Baseline | 63.4 | Standard Deviation 22.55 | Score on a Scale |
Change From Baseline in the European Organization for Research and Treatment of Care Quality-of-Life Questionnaire (EORTC QLQ-C30) Global Health Status Score in All Randomized Participants for Primary Study | Treatment 2 | Global Health Status - Baseline | 59.8 | Standard Deviation 25.05 | Score on a Scale |
Change From Baseline in the European Organization for Research and Treatment of Care Quality-of-Life Questionnaire (EORTC QLQ-C30) Global Health Status Score in All Randomized Participants for Primary Study | Treatment 1 | Global Health Status - Week 4 | -1.1 | Standard Deviation 18.28 | Score on a Scale |
Change From Baseline in the European Organization for Research and Treatment of Care Quality-of-Life Questionnaire (EORTC QLQ-C30) Global Health Status Score in All Randomized Participants for Primary Study | Treatment 2 | Global Health Status - Week 4 | 2.7 | Standard Deviation 23.21 | Score on a Scale |
Change From Baseline in the European Organization for Research and Treatment of Care Quality-of-Life Questionnaire (EORTC QLQ-C30) Global Health Status Score in All Randomized Participants for Primary Study | Treatment 1 | Global Health Status - Week 10 | -0.5 | Standard Deviation 23.73 | Score on a Scale |
Change From Baseline in the European Organization for Research and Treatment of Care Quality-of-Life Questionnaire (EORTC QLQ-C30) Global Health Status Score in All Randomized Participants for Primary Study | Treatment 2 | Global Health Status - Week 10 | 3.0 | Standard Deviation 23.55 | Score on a Scale |
Change From Baseline in the European Organization for Research and Treatment of Care Quality-of-Life Questionnaire (EORTC QLQ-C30) Global Health Status Score in All Randomized Participants for Primary Study | Treatment 1 | Global Health Status - Week 16 | 3.6 | Standard Deviation 22.59 | Score on a Scale |
Change From Baseline in the European Organization for Research and Treatment of Care Quality-of-Life Questionnaire (EORTC QLQ-C30) Global Health Status Score in All Randomized Participants for Primary Study | Treatment 2 | Global Health Status - Week 16 | 3.1 | Standard Deviation 24.68 | Score on a Scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03036098/results